KTC
ALXN

Kistler-Tiffany Companies’s Alexion Pharmaceuticals ALXN Stock Holding History

Kistler-Tiffany Companies’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-16
Closed -$2K – 724
2016
Q2 		$2K Buy
+16
New +$2.27K ﹤0.01% 566

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Kistler-Tiffany Companies's ALXN Position: Q3 2016 in Review

Kistler-Tiffany Companies sold out of Alexion Pharmaceuticals (ALXN) in Q3 2016, closing a stake of 16 shares — an estimated $2K sold.

Kistler-Tiffany Companies first reported a position in ALXN in Q2 2016 and held it in 1 quarter. The position peaked at $2K in Q2 2016. 518 funds tracked by Wall St. Rank hold ALXN as of Q3 2016.

  • Kistler-Tiffany Companies reported no remaining Alexion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 16 Alexion Pharmaceuticals shares in Q3 2016, an estimated $2K.
  • Kistler-Tiffany Companies first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Kistler-Tiffany Companies's Alexion Pharmaceuticals position peaked at $2K in Q2 2016.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2016.

Based on Kistler-Tiffany Companies's 13F filing for Q3 2016, filed 8 Nov 2016.